Biocryst Pharmaceuticals (BCRX -3.88%) and Dyax Corp. (NASDAQ: DYAX) both rose yesterday on good news from Biocryst's phase 2A trial for BCX4161, a drug designed to treat hereditary angioedema (also known as HAE). Patients treated with BCX4161 had a statistically significant 35% decline in HAE attacks, and although the trial was small, the data appear encouraging. Dyax is also developing an HAE drug, DX-2930, and a Jefferies analyst noted that the positive news for Biocryst provides some reason for optimism for Dyax's drug (which is in early stage clinical trials) as well.
But which stock is the better buy? In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson give their take on which stock they'd prefer to own.
